Authors
Latest:
Mario Sznol, MD, on Patient Selection for Combination Therapy in mRCCMario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.
Latest:
Dr. Gutierrez on Biomarker-Directed Precision Oncology of Pembrolizumab-Based Combos in NSCLCMartin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.
Latest:
Dr. McCulloch on the Use of R-BAC in MCL After Progression on BTK TherapyRory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the use of R-BAC (rituximab [Rituxan],bendamustine, and cytarabine) in patients with mantle cell lymphoma (MCL) who had progressed on initial therapy with a BTK inhibitor.
Latest:
Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCCRichard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).
Latest:
Dr. Choueiri on Subsequent Combo Therapy After PD-1/PD-L1 Blockade in RCCToni Choueiri, MD, discusses what therapy to give patients with renal cell carcinoma after they have received a PD-1/PD-L1 blockade.
Latest:
Dr. Mudad on RELAY Trial for EGFR-Mutant NSCLCRaja Mudad, MD, FACP, discusses the RELAY trial and using doublet therapy to treat EGFR-mutant non–small cell lung cancer.
Latest:
First-Line Necitumumab Improves Survival in Metastatic Squamous NSCLCA phase III trial exploring necitumumab plus chemotherapy as a first-line therapy for patients with metastatic squamous non-small cell lung cancer has demonstrated an improvement in overall survival when compared to chemotherapy alone.
Latest:
Dr. Robert Motzer Reviews the Phase III COMPARZ StudyRobert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.
Latest:
Dr. Vogelzang Discusses First-Line Axitinib in mRCCNicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.
Latest:
Dr. Bollard on the Treatment of EBV-Positive LymphomaCatherine Bollard, MBChB, MD, Professor of Pediatrics, Medicine, and Pathology & Immunology, Baylor College of Medicine, discusses the treatment of EBV-positive lymphoma with T-cell therapy.
Latest:
Dr. Sarah Holstein on Lenalidomide Maintenance UpdatesSarah Holstein, MD, PhD, Assistant Professor of Oncology, Lymphoma/Myeloma Service Department of Medicine, Roswell Park Cancer Institute, discusses an updated of analysis CALGB/ECOG/BMT CTN 100104, which investigated lenalidomide maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma.
Latest:
Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell CarcinomaBrian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.
Latest:
Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALLStephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).
Latest:
Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCCMark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.
Latest:
Investigators Seek Expanded Use of Checkpoint Inhibitors in RCCIn contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.
Latest:
Dr. Cavo on Upfront ASCT in Multiple MyelomaMichele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.
Latest:
Dr. Ferris on Significance of CheckMate-141 Trial for Head and Neck CancerRobert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).
Latest:
Expert Discusses Neoadjuvant Treatment Potential in Advanced RCCNeoadjuvant therapy is evolving as a treatment approach for patients with advanced renal cell carcinoma.
Latest:
Dr. Haas on Adjuvant VEGF-Targeted Therapy in RCCNaomi B. Haas, MD, director, Prostate and Kidney Cancer Program Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses results of 2 ongoing clinical trials looking at adjuvant therapy options in renal cell carcinoma (RCC).
Latest:
Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard TherapyAccording to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.
Latest:
Study Finds Hyperprogression After Immunotherapy in NSCLC SubsetAlthough anti-PD-1/PD-L1 immunotherapy has greatly improved the treatment of patients with non–small cell lung cancer and is generally well-tolerated, the therapy backfires in a newly defined subset of patients who experience accelerated tumor growth indicative of hyperprogressive disease.
Latest:
Lenalidomide Plus Rituximab Safe and Effective as Initial Treatment for MCLLenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.
Latest:
New Hairy Cell Leukemia Therapy Aims to Produce Complete RemissionsRobert J. Kreitman, MD, discusses key attributes of moxetumomab pasudotox and its potential impact in hairy cell leukemia.
Latest:
Dr. Lugtenburg on Maintenance Rituximab in DLBCLPieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.
Latest:
Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell LeukemiaAgnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.
Latest:
Renal Cell Carcinoma Vaccine Fails to Improve OutcomesThe IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.
Latest:
Dr. Crinò on Crizotinib in ALK-Positive NSCLCLucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer
